Subjects -> MEDICAL SCIENCES (Total: 8359 journals)
    - ALLERGOLOGY AND IMMUNOLOGY (210 journals)
    - ANAESTHESIOLOGY (119 journals)
    - CARDIOVASCULAR DISEASES (329 journals)
    - CHIROPRACTIC, HOMEOPATHY, OSTEOPATHY (21 journals)
    - COMMUNICABLE DISEASES, EPIDEMIOLOGY (228 journals)
    - DENTISTRY (288 journals)
    - DERMATOLOGY AND VENEREOLOGY (162 journals)
    - EMERGENCY AND INTENSIVE CRITICAL CARE (119 journals)
    - ENDOCRINOLOGY (148 journals)
    - FORENSIC SCIENCES (41 journals)
    - GASTROENTEROLOGY AND HEPATOLOGY (182 journals)
    - GERONTOLOGY AND GERIATRICS (132 journals)
    - HEMATOLOGY (153 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (164 journals)
    - LABORATORY AND EXPERIMENTAL MEDICINE (98 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2268 journals)
    - NURSES AND NURSING (356 journals)
    - OBSTETRICS AND GYNECOLOGY (202 journals)
    - ONCOLOGY (377 journals)
    - OPHTHALMOLOGY AND OPTOMETRY (136 journals)
    - ORTHOPEDICS AND TRAUMATOLOGY (164 journals)
    - OTORHINOLARYNGOLOGY (80 journals)
    - PATHOLOGY (96 journals)
    - PEDIATRICS (270 journals)
    - PHYSICAL MEDICINE AND REHABILITATION (152 journals)
    - PSYCHIATRY AND NEUROLOGY (813 journals)
    - RADIOLOGY AND NUCLEAR MEDICINE (190 journals)
    - RESPIRATORY DISEASES (102 journals)
    - RHEUMATOLOGY (76 journals)
    - SPORTS MEDICINE (78 journals)
    - SURGERY (393 journals)
    - UROLOGY, NEPHROLOGY AND ANDROLOGY (150 journals)

RESPIRATORY DISEASES (102 journals)                     

Showing 1 - 102 of 102 Journals sorted alphabetically
Advances in Respiratory Medicine     Open Access   (Followers: 7)
American Journal of Respiratory and Critical Care Medicine     Full-text available via subscription   (Followers: 253)
American Journal of Respiratory Cell and Molecular Biology     Full-text available via subscription   (Followers: 20)
American Review of Respiratory Disease     Full-text available via subscription   (Followers: 4)
Angiologia e Cirurgia Vascular     Open Access   (Followers: 1)
Annals of the American Thoracic Society     Full-text available via subscription   (Followers: 16)
Annals of Thoracic Medicine     Open Access   (Followers: 6)
Archivos de Bronconeumología     Full-text available via subscription  
Archivos de Bronconeumología (English Edition)     Full-text available via subscription   (Followers: 1)
Asthma Research and Practice     Open Access   (Followers: 1)
BMC Pulmonary Medicine     Open Access   (Followers: 4)
BMJ Open Respiratory Research     Open Access   (Followers: 5)
Breathe     Open Access   (Followers: 4)
Canadian Journal of Respiratory, Critical Care, and Sleep Medicine     Hybrid Journal  
Canadian Respiratory Journal     Open Access   (Followers: 2)
Case Reports in Pulmonology     Open Access   (Followers: 3)
Chest     Full-text available via subscription   (Followers: 100)
Chest Disease Reports     Open Access   (Followers: 2)
Chronic Respiratory Disease     Hybrid Journal   (Followers: 9)
Clinical Lung Cancer     Hybrid Journal   (Followers: 5)
Clinical Medicine Insights : Circulatory, Respiratory and Pulmonary Medicine     Open Access   (Followers: 3)
Clinical Pulmonary Medicine     Hybrid Journal   (Followers: 2)
COPD Research and Practice     Open Access   (Followers: 1)
COPD: Journal of Chronic Obstructive Pulmonary Disease     Hybrid Journal   (Followers: 15)
Current Opinion in Pulmonary Medicine     Hybrid Journal   (Followers: 10)
Current Pulmonology Reports     Hybrid Journal  
Current Research in Tuberculosis     Open Access   (Followers: 3)
Current Respiratory Care Reports     Hybrid Journal   (Followers: 1)
Current Respiratory Medicine Reviews     Hybrid Journal   (Followers: 5)
Der Pneumologe     Hybrid Journal   (Followers: 1)
Egyptian Journal of Chest Diseases and Tuberculosis     Open Access   (Followers: 3)
ERJ Open Research     Open Access   (Followers: 2)
Eurasian Journal of Pulmonology     Open Access  
European Clinical Respiratory Journal     Open Access   (Followers: 3)
European Respiratory Journal     Full-text available via subscription   (Followers: 38)
European Respiratory Review     Open Access   (Followers: 7)
Experimental Lung Research     Hybrid Journal  
Expert Review of Respiratory Medicine     Hybrid Journal   (Followers: 5)
Heart & Lung: The Journal of Acute and Critical Care     Hybrid Journal   (Followers: 11)
Heart, Lung and Circulation     Full-text available via subscription   (Followers: 9)
Indian Journal of Respiratory Care     Open Access   (Followers: 3)
Indian Journal of Tuberculosis     Full-text available via subscription  
Influenza and Other Respiratory Viruses     Open Access   (Followers: 2)
International Journal of Chronic Obstructive Pulmonary Disease     Open Access   (Followers: 3)
Journal of Association of Chest Physicians     Open Access   (Followers: 2)
Journal of Asthma     Hybrid Journal   (Followers: 4)
Journal of Asthma Allergy Educators     Hybrid Journal   (Followers: 4)
Journal of Bronchology & Interventional Pulmonology     Hybrid Journal   (Followers: 3)
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases     Open Access  
Journal of Heart and Lung Transplantation     Hybrid Journal   (Followers: 12)
Journal of Respiratory Medicine     Open Access   (Followers: 4)
Journal of Respiratory Research     Open Access   (Followers: 1)
Journal of Tuberculosis Research     Open Access   (Followers: 1)
Jurnal Respirasi     Open Access  
Karger Kompass Pneumologie     Full-text available via subscription   (Followers: 1)
Kindheit und Entwicklung     Hybrid Journal  
Lung     Hybrid Journal   (Followers: 2)
Lung Cancer     Hybrid Journal   (Followers: 15)
Lung Cancer International     Open Access   (Followers: 2)
Lung Cancer: Targets and Therapy     Open Access   (Followers: 3)
Lung India     Open Access   (Followers: 1)
Multidisciplinary Respiratory Medicine     Open Access   (Followers: 4)
npj Primary Care Respiratory Medicine     Open Access   (Followers: 2)
Open Journal of Respiratory Diseases     Open Access   (Followers: 1)
Open Respiratory Medicine Journal     Open Access   (Followers: 1)
Paediatric Respiratory Reviews     Hybrid Journal   (Followers: 11)
Pediatric Quality & Safety     Open Access  
Pediatric Respirology and Critical Care Medicine     Open Access   (Followers: 1)
Pulmonary Circulation     Open Access   (Followers: 4)
Pulmonary Medicine     Open Access   (Followers: 2)
Pulmonary Pharmacology & Therapeutics     Hybrid Journal   (Followers: 2)
Pulmonary Therapy     Open Access   (Followers: 1)
Pulmonology and Respiratory Research     Open Access   (Followers: 1)
Respiratory Care     Full-text available via subscription   (Followers: 10)
Respiratory Investigation     Full-text available via subscription  
Respiratory Medicine     Hybrid Journal   (Followers: 17)
Respiratory Medicine : X     Open Access  
Respiratory Medicine Case Reports     Open Access  
Respiratory Medicine CME     Hybrid Journal  
Respiratory Medicine Extra     Full-text available via subscription   (Followers: 1)
Respiratory Physiology & Neurobiology     Hybrid Journal   (Followers: 4)
Respiratory Research     Open Access   (Followers: 1)
Respirology     Hybrid Journal   (Followers: 5)
Respirology Case Reports     Open Access  
Revista Americana de Medicina Respiratoria     Open Access  
Revista Chilena de Enfermedades Respiratorias     Open Access  
Revista Inspirar     Open Access  
Revista ORL     Open Access  
Revista Portuguesa de Pneumologia     Open Access  
Sarcoidosis Vasculitis and Diffuse Lung Disese     Full-text available via subscription   (Followers: 3)
Seminars in Respiratory and Critical Care Medicine     Hybrid Journal   (Followers: 14)
Sleep Medicine Reviews     Hybrid Journal   (Followers: 17)
The Clinical Respiratory Journal     Hybrid Journal   (Followers: 3)
The International Journal of Tuberculosis and Lung Disease     Full-text available via subscription   (Followers: 8)
The Lancet Respiratory Medicine     Full-text available via subscription   (Followers: 32)
Therapeutic Advances in Chronic Disease     Open Access   (Followers: 7)
Therapeutic Advances in Respiratory Disease     Open Access   (Followers: 1)
Thorax     Hybrid Journal   (Followers: 37)
Translational Respiratory Medicine     Open Access   (Followers: 1)
Tuberculosis     Hybrid Journal   (Followers: 12)
Tuberculosis Research and Treatment     Open Access   (Followers: 3)
Пульмонология     Full-text available via subscription  

           

Similar Journals
Journal Cover
Revista Chilena de Enfermedades Respiratorias
Number of Followers: 0  

  This is an Open Access Journal Open Access journal
ISSN (Print) 0717-5698 - ISSN (Online) 0717-7348
Published by SciELO Homepage  [888 journals]
  • Origin and natural history of asthma

    •  
  • Comparative study of the categorization of COPD patients based on GOLD
           2007, 2011 and 2019

    • Abstract: Resumen Introducción: La Enfermedad Pulmonar Obstructiva Crónica afecta a 260 millones de personas a nivel mundial y representará la tercera causa de muerte para el año 2020. Materiales y Métodos: Se realizó un estudio observacional descriptivo transversal con la finalidad de comparar la estadificación de un grupo de pacientes venezolanos con EPOC según la Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2007, 2011 y 2019. Resultados: La muestra estuvo constituida por ochenta y nueve (89) pacientes con una edad promedio de 66,7 ± 0,9 años, siendo el 60,7% de los pacientes del sexo masculino y 82% fumadores. El 14,6% de los pacientes presentaban EPOC leve, 36% EPOC moderado, 41,6% EPOC severo y 7,9% EPOC muy severo. El valor del test Kappa de Cohen entre las escalas mMRC y CAT (COPD Assessment Test) fue de 0,529 (GOLD 2011) y 0,555 (GOLD 2019). Conclusiones: 1) la poca concordancia entre el VEF1, grado de disnea e historial de exacerbaciones impacta la clasificación de la severidad de la EPOC al utilizar GOLD 2011; 2) la concordancia moderada entre las escalas mMRC y CAT sugiere que el tipo de cuestionario utilizado afecta la categorización de la severidad de la enfermedad; 3) los pacientes del grupo B mostraron una importante afectación en el intercambio gaseoso dado por valores más bajos de DLCO y oximetría arterial y 4) una proporción significativa de pacientes fueron clasificados en los grupos de alto riesgo (B y D) en GOLD 2011 y 2019. Introduction: Chronic Obstructive Pulmonary Disease (COPD) affects 260 million people worldwide and it is thought to become the third leading cause of mortality by the year 2020. Materials and Methods: A transversal descriptive observational study was conducted to compare the categorization of a group of Venezuelan COPD patients according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2007, 2011 and 2019. Results: Eighty-nine (89) patients with a mean age of 66.7 ± 0.9 years were included, 60.7% were male and 82% smokers. 14.6% of the patients had mild COPD, 36% moderate COPD, 41.6% severe COPD and 7.9% very severe COPD. Cohen's Kappa coefficient value between mMRC and COPD Assessment test (CAT) was 0,529 (GOLD 2011) and 0,555 (GOLD 2019). Conclusions: 1) the lack of concordance between FEV1 values, degree of dyspnea and history of exacerbations impacts COPD severity classification when using GOLD 2011; 2) moderate agreement between mMRC and CAT scales suggests that the type of questionnaire used to evaluate perception of dyspnea can affect disease severity categorization; 3) group B patients showed a significant gas exchange impairment due to lower values of DLCO and arterial oxymetry and 4) a significant proportion of patients were categorized in the high-risk groups (B and D) both in GOLD 2011 and 2019. Optimization of the evaluation of COPD severity is important to allow a better standardization of care and pharmacological management of patients with this disease.
       
  • Impact of pollution by particulate matter on emergency room admissions for
           respiratory causes in Chillán, Concepción, and Los Ángeles, Chile

    • Abstract: Resumen Objetivo: Determinar el impacto de la contaminación del aire sobre la salud respiratoria en las comunas de Chillán, Concepción y Los Ángeles entre los años 2013 y 2017. Material y Métodos: Se estimaron modelos lineales generalizados (GLM) a partir de datos diarios de atenciones de urgencias por enfermedades respiratorias desagregadas por tipo y rango etario, concentraciones de material particulado respirable (MP10) y material particulado fino (MP2,5), índice viral, variables meteorológicas y estacionales. Resultados: Se obtiene una asociación positiva entre los contaminantes analizados y las atenciones de urgencias por causas respiratorias, especialmente IRA alta y Bronquitis/Bronquiolitis aguda en Chillán, IRA alta en Concepción, y además, IRA alta, Influenza y Crisis Obstructiva Bronquial en Los Ángeles. Conclusiones: El incremento en el número de todas las atenciones de urgencia es aproximadamente 18.695 al año por cada 1 μg/m3 de incremento en las concentraciones de material particulado. Objective: To determine the impact of air pollution on respiratory diseases in the districts of Chillán, Concepción and Los Ángeles, Chile between 2013 and 2017. Material and Methods: Generalized linear models (GLM) were estimated from daily data for emergency room admissions disaggregated by type and age range, concentrations of respirable particulate matter (PM10) and fine particulate matter (PM2.5), viral index, meteorological and seasonal variables. Results: A positive association is obtained between the analyzed contaminants and the number of emergency room admissions for respiratory causes, especially acute upper respiratory infection (URI) and acute bronchitis / bronchiolitis in Chillán, acute URI in Concepción, and also, acute URI, Influenza and obstructive bronchial crisis in Los Angeles. Conclusions: The increase in the total number of emergency room admissions is approximately 18,695 per year for every 1 μg / m3 increase in PM concentrations.
       
  • Invasive pulmonary aspergillosis in rheumatological patients. Presentation
           of two cases

    • Abstract: Resumen La aspergilosis pulmonar invasora (API) es una infección causada por hongos del género Aspergillus que afecta principalmente a pacientes inmunocomprometidos y corresponde a la forma más grave de aspergilosis. Se asocia a una alta morbi-mortalidad, siendo fundamental un diagnóstico y tratamiento oportuno. Las manifestaciones clínicas son inespecíficas, por lo que un estudio adecuado es importante para el diagnóstico, principalmente en pacientes con factores de riesgo poco habituales. En la actualidad se han establecido categorías diagnósticas que consideran factores del hospedero, laboratorio micológico tradicional y biomarcadores como galactomanano. Éstos, junto a la mejor comprensión e interpretación de las imágenes tomográficas permiten ofrecer un manejo adecuado. En este artículo, se presentan dos casos clínicos de API en pacientes reumatológicos, y se discute la utilidad de los métodos diagnósticos.Invasive pulmonary aspergillosis (IPA) is an infection caused by fungi of the genus Aspergillus that mainly affects immunocompromised patients and corresponds to the most severe form of aspergillosis. It is associated with high morbidity and mortality, and diagnosis and timely treatment are essential. Clinical manifestations are nonspecific, so an adequate study is important for diagnosis, mainly in patients with unusual risk factors. At present, diagnostic categories have been established that consider factors of the host, traditional mycological laboratory and biomarkers such as galactomannan. These, together with the better understanding and interpretation of the tomographic images, allow us to offer an adequate management. In this article, two clinical cases of API in rheumatological patients are presented, and the usefulness of the diagnostic methods is discussed.
       
  • Crazy paving computed tomography pattern in a young woman. Unexpected
           findings and non-traditional treatment in a pulmonary alveolar proteinosis
           case

    • Abstract: Resumen El patrón llamado ‘crazy paving’ en tomografia computada de tórax (TAC) puede deberse a diferentes condiciones siendo una de ellas la Proteinosis Alveolar Pulmonar (PAP), rara condición que puede llevar a insuficiencia respiratoria y a menudo, a la muerte. Presentamos el caso de una mujer joven con una historia de un año de evolución de disnea progresiva y tos seca que consultó por un cuadro de aparición brusca de fiebre, calofríos, malestar general y falla respiratoria hipoxémica severa (PaO2 = 51,9 mmHg con FiO2 = 0,50) en la cual la TAC de tórax mostraba un patrón de empedrado o ‘crazy paving’ que significó un desafío diagnóstico resuelto finalmente con una biopsia pulmonar quirúrgica que mostró una PAP. Ante el fracaso del tratamiento tradicional de Lavado Pulmonar Total (LPT) se usó una aproximación terapéutica novedosa consistente en una serie de 4 lavados lobares con un perfluorocarbono, Perflubron (PFC) bajo anestesia local seguido por 5 sesiones de Plasmaféresis. Casi inmediatamente después de este tratamiento la paciente evidenció mejoría radiológica y funcional. La PaO2 fue de 89,9 mmHg respirando aire ambiental y la CVF y el VEF1 aumentaron alcanzado respectivamente el 77 y el 75% de sus valores normales de referencia. Dadas las características químicas y físicas del PFC, pensamos que es una alternativa válida al LPT en estos casos.Crazy paving computed tomography pattern may be due to a number of causes, one of them being Pulmonary Alveolar Proteinosis, a rare condition leading to respiratory failure and often to death. We present the case of a young woman with a one-year history of progressive dyspnea and dry cough, who consulted for an acute onset of fever, chills, malaise and severe hypoxemic respiratory failure (PaO2 = 51.9 mmHg; FiO2 = 0.50) with a ‘crazy paving' pattern on chest CT. This diagnostic challenge was resolved by a surgical lung biopsy that showed a pulmonary alveolar proteinosis. Taking into account that the traditional treatment using whole lung lavage had already failed in this patient, a novel therapeutic approach was settled. A series of 4 lobar lavages with a perfluorocarbon (Perflubron) under local anesthesia followed by 5 plasmapheresis sessions were carried out. The patient showed radiographic and functional improvement almost immediately after this treatment. PaO2 was 89.9 mmHg breathing room air and FVC and FEV1 increased to reach 77 and 75% respectively of their normal reference values. Because of its chemical and physical properties we think this novel therapeutic approach should be a valuable alternative to saline solution for whole lung lavage in these cases.
       
  • Pulmonary alveolar proteinosis an update

    • Abstract: Resumen La Proteinosis Alveolar Pulmonar (PAP) es una enfermedad poco frecuente, caracterizada por la acumulación de material lipoproteico derivado del surfactante pulmonar al interior de los alvéolos por una falla de depuración de este material por los macrófagos alveolares, siendo la causa más frecuente de esta disfunción la acción bloqueadora producida por anticuerpos anti factor estimulante de colonias de granulocitos y macrófagos (GM-CSF) lo que lleva a un deterioro del intercambio gaseoso. La evolución es variable abarcando desde la resolución espontánea hasta la insuficiencia respiratoria grave y la muerte. Se describen tres formas de PAP: Genética, secundaria y autoinmune (antes primaria o idiopática) siendo esta última la más frecuente en adultos. Clínicamente, se manifiesta por disnea, tos seca e hipoxemia que pueden ser progresivas. En la radiografía de tórax se encuentran opacidades bilaterales y la tomografía computarizada de tórax de alta resolución (TACAR) muestra vidrio esmerilado con sobre posición de engrosamiento septal intra e interlobulillar, patrón conocido como “crazy paving”. El diagnóstico se basa en la clínica y en el lavado broncoalveolar con material PAS positivo. La biopsia quirúrgica es confirmatoria. El tratamiento clásico es el lavado pulmonar total (LPT) para remover el contenido alveolar. Otras alternativas son la administración de GM-CSF subcutáneo o inhalado, plasmaferesis y rituximab, cuyos resultados son variables. Diferentes autores han modificado la forma del LPT y combinado los diferentes métodos de tratamiento con el fin de obtener resultados más rápidos y efectivos.Pulmonary Alveolar Proteinosis (PAP) is a rare disease characterized by the accumulation of surfactant derived lipoproteinaceous material filling the alveoli, secondary to failure of its clearance by macrophages. Most of the patients are adults that have auto antibodies directed to Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF). The evolution is towards disturbed gaseous exchange with a wide spectrum of disease from spontaneous recovery to death. There are three forms of PAP: genetic, secondary and autoimmune. Symptoms are scarce and patients may present with dyspnea, dry cough and hypoxemia. Chest X ray shows bilateral opacities and thorax CT depicts ground glass opacities surrounded by septal widening, the so called “crazy paving” pattern. Diagnosis is made on clinical and radiological grounds and confirmed by PAS positive staining of bronchoalveolar lavage material or surgical lung biopsy. Accepted treatment is whole lung lavage (WLL) with saline. Alternatives are subcutaneous or inhaled GM-CSF, Plasmapheresis or Rituximab, and even modification of the method of WLL and combination of different manner of treatment.
       
  • Role of bacterial lysates in asthma, evidence and projection with special
           reference to OM-85

    • Abstract: Resumen Existen diversos lisados bacterianos, siendo OM-85 (Broncho-Vaxom®) el que posee mayor evidencia en cuanto a su rol inmunoprotector sobre infecciones respiratorias en población pediátrica. Sus mecanismos de acción producen efectos inmunomoduladores que potencialmente podrían prevenir el asma en etapas precoces de la vida, actuar sobre la disminución de crisis y ser un aporte a la terapia convencional del asma. Este artículo expone las principales evidencias en relación con estos compuestos, con enfoque en la actualidad y el desarrollo futuro, en especial sobre OM-85.There are several bacterial lysates, being OM-85 (Broncho-Vaxom®) the one with the greatest evidence regarding its immunoprotective role on respiratory infections in the pediatric population. Its mechanisms of action produce immunomodulatory effects that could potentially prevent asthma in early stages of life, act on the reduction of crisis and be a contribution to conventional asthma therapy. This article shows the main evidences in relation to these compounds, the current focus and future development, especially on OM-85.
       
  • Heated tobacco products with special reference to IQOS

    • Abstract: Resumen Los Productos de Tabaco Calentado (PTC) son nuevos dispositivos de consumo de tabaco que se presentan como un producto de reducción del daño. El más difundido es IQOS de Philip Morris. En el aerosol de IQOS se detectan sustancias tóxicas en menor cantidad y concentración que las detectadas en el humo del cigarrillo convencional, a excepción de algunas. Estas sustancias son capaces de producir enfermedad, con alteración de las células del epitelio bronquial y del endotelio vascular y podría producir nuevos daños, como hepato-toxicidad. La cantidad de nicotina de IQOS es muy similar a los cigarrillos convencionales, por lo que es tan adictivo como el cigarrillo normal. La concentración de sustancias tóxicas emitidas al medio ambiente es menor que las del cigarrillo convencional, pero hay riesgo para la salud de los no fumadores expuestos. La mayoría de las personas usan los PTC como complemento a los cigarrillos convencionales, no como alternativa, transformándose en fumadores duales. IQOS puede crear nuevas generaciones adictas a la nicotina, además de renormalizar el consumo de tabaco en la sociedad. Muchas Sociedades Médicas de Enfermedades Respiratorias en el mundo se han manifestado en contra del uso de los PTC, y han propuesto que deben regirse bajo las mismas políticas regulatorias que se aplican a todos los productos de tabaco, en línea con lo establecido por el Convenio Marco de Control del Tabaco de la OMS.Heated Tobacco Products (HTP) are new tobacco consumption devices that are presented as a harm reduction product. The most widespread is IQOS by Philip Morris. In the IQOS aerosol, toxic substances are detected in a smaller amount and concentration than those detected in conventional cigarettes, with the exception of some of them. These substances are able of inducing disease. They could modify bronchial epithelial cells and vascular endothelium and could cause additional damages, such as hepatotoxicity The amount of nicotine in IQOS is very similar to conventional cigarettes, so it is as addictive as a normal cigarette. The concentration of toxic substances emitted to the environment is lower than those of conventional cigarettes, but there is a health's risk of exposed non-smokers. Most people use HTP as a complement to conventional cigarettes, not as an alternative, becoming dual smokers. IQOS can create new generations addicted to nicotine, in addition to renormalize the tobacco's use in society. Many Medical Societies of Respiratory Diseases around the world have manifested against the use of HTP, and have proposed that they should be subject to the same regulatory policies that applied to all tobacco products, in line with the WHO Framework Convention on Tobacco Control.
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 100.26.179.196
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-